Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study)

aDepartment of Epidemiology and Training, Epicentre, Médecins Sans Frontières, Paris, France;

bUniv. Bordeaux, INSERM, BPH, U1219, Bordeaux, France;

cCHU de Bordeaux, COREVIH Nouvelle Aquitaine, Bordeaux, France;

dCHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Bordeaux, France;

eCH de la Côte Basque, Service de maladies infectieuses, Centre Hospitalier de la Côte Basque, Bayonne, France;

fCHU de Bordeaux, Service des Maladies Infectieuses et Tropicales, Bordeaux, France;

gCH de François Mitterrand de Pau, Pau, France;

hCH de Libourne Robert Boulin, Libourne, France;

iCHU de Bordeaux, Service de Médecine Interne, Pessac, France;

jCH de Périgueux, Service de Médecine Polyvalente, Périgueux, France;

kCentre Hospitalier Agen-Nérac, Agen, France;

lDepartment of Immunology, UMR 5164, ImmunoConcEpT, CNRS, Bordeaux, France;

mUniv. Bordeaux, INSERM, Institut Bergonié, BPH, U1219, CIC-EC 1401, Bordeaux, France;

nINRIA SISTM team, Talence, France; and

oCHU de Bordeaux, Service d'information médicale, INSERM, Institut Bergonié, CIC-EC 1401, Bordeaux, France.

Correspondence to: Jihane Ben Farhat, BPH, Université de Bordeaux, 146 rue Léo Sagnat 11, 33076 Bordeaux, France (e-mail: [email protected]).

This ANRS CO3 AQUIVIH-NA Cohort received fundings from ANRS | MIE and CHU de Bordeaux. D.B. has received post-doctoral funding from the ANRS|MIE (grant number: ECTZ117276 2020-1).

The authors declare no conflicts of interest in relation to this manuscript. S.F. has received financial support from Gilead Sciences, MSD and ViiV Healthcare to attend scientific conferences. D.B. has received speaking fees from Gilead Healthcare, MSD, ViiV Healthcare and outside the submitted work.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

The ANRS CO3 AQUIVIH-NA Cohort received approval from the Comité de Protection des Personnes (CPP) du Sud-Ouest et d’Outre-Mer III (May 25, 2016).

Informed consent was obtained from all individual included in the cohort.

The data that support the findings of this study are available on reasonable request from the corresponding author.

F.B. and D.B. contributed equally.

留言 (0)

沒有登入
gif